ASTORG takes majority stake in CORDENPHARMA

Astorg has entered into an agreement to acquire CordenPharma from International Chemical Investors Group (ICIG), a leading pharmaceutical contract development and manufacturing organization (CDMO) specializing in complex drug development and manufacturing. CordenPharma covers the full pharmaceutical lifecycle, from early-stage development through to large-scale commercial production. The company operates a diversified technology platform spanning peptides, lipids and carbohydrates, highly potent active pharmaceutical ingredients (HPAPIs), injectables and small molecules. This multi-technology setup enables CordenPharma to address increasingly complex pharmaceutical requirements across high-growth therapeutic areas including oncology, metabolic diseases and advanced modalities. CordenPharma operates an integrated industrial footprint with R&D and manufacturing sites across Europe and the United States, providing end-to-end development, scale-up and multi-site production capabilities. The group serves a broad base of leading global pharmaceutical and biotechnology customers. As part of the transaction, management and founding shareholders are expected to reinvest alongside Astorg, reflecting strong alignment around the company’s future growth strategy.